The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L.
Koji Takeda
No relevant relationships to disclose
Fumihiko Hirai
No relevant relationships to disclose
Takeharu Yamanaka
No relevant relationships to disclose
Kenichi Taguchi
No relevant relationships to disclose
Haruko Daga
No relevant relationships to disclose
Junichi Shimizu
No relevant relationships to disclose
Yoshihito Kogure
No relevant relationships to disclose
Tatsuo Kimura
No relevant relationships to disclose
Kaoru Tanaka
No relevant relationships to disclose
Yasuo Iwamoto
No relevant relationships to disclose
Akira Ono
No relevant relationships to disclose
Hidefumi Sasaki
No relevant relationships to disclose
Junya Fukuoka
Employment or Leadership Position - Pathology Institute Corp. (U)
Stock Ownership - Pathology Institute Corp.
Kenichi Nishiyama
No relevant relationships to disclose
Takashi Seto
Honoraria - Bristol-Myers Squibb
Yukito Ichinose
Honoraria - Bristol-Myers Squibb
Kazuhiko Nakagawa
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Yoichi Nakanishi
No relevant relationships to disclose